HSP90 inhibitors have shown activity in EGFR mutant lung cancer after the development of resistance, in ALK-rearranged tumors and more recently in EGFR wild type adenocarcinoma when combined with chemotherapy (59). This evidence concerns the gene ALK and adenocarcinoma.